Continuous Heparin Infusion to Prevent Catheter-related Thrombosis
Primary Purpose
Cardiac Surgery, Central Venous Catheter Thrombosis, Heparin
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Heparin sodium
Normal saline
Sponsored by
About this trial
This is an interventional prevention trial for Cardiac Surgery
Eligibility Criteria
Inclusion Criteria:
- less than 3 months of age at admission, post-cardiac surgery, with CVC indwelled
Exclusion Criteria:
- parents' refusal, requiring postoperative anticoagulant administration (extracorporeal membrane oxygenation support, prosthetic devices), the contradiction to heparin (coagulopathy or hypercoagulable state, platelet level less than 50000/dL, clinically significant bleeding tendency, allergy to heparin)
Sites / Locations
- Guangdong Provincial People's Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Heparin group
Control group
Arm Description
Continuous infusion of heparin was used to maintain the patency of CVC.
Continuous infusion of heparin was used at the corresponding speed.
Outcomes
Primary Outcome Measures
124 infants of CVC-related thrombosis by point-of-care echography or ultrasound
CVC-related thrombosis of any catheter as imaged by echocardiogram or ultrasound at 30 days after cardiac surgery. Thrombus was defined as an echogenic mass near the tip of the catheter or slow/no flow detected by Duplex and Doppler ultrasound at the nearby vessels and the on-site vessel couldn't be clasped as narrow as the collateral vessel by compression of the probe.
Secondary Outcome Measures
124 infants of heparin-related comorbidity
Abnormal coagulation and hemostasis were defined as treatment initiation by the clinical teams at the discretion of heparin adverse events. Heparin-induced thrombocytopenia was confirmed with consistent low platelet level and positive enzyme-linked immunosorbent assay heparin-platelet factor 4 antibody assay. Catheter-related sepsis was defined as culture of the same organism from both the catheter tip and at least one percutaneous blood culture. Culture of the same organism from the catheter was also accepted as an alternative of culture of catheter tip.
Full Information
NCT ID
NCT04767113
First Posted
February 6, 2021
Last Updated
August 31, 2022
Sponsor
Guangdong Provincial People's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04767113
Brief Title
Continuous Heparin Infusion to Prevent Catheter-related Thrombosis
Official Title
A Randomized, Controlled Trial of Continuous Heparin Versus Placebo Infusion to Prevent Catheter-related Thrombosis in Infants After Cardiac Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
September 2022
Overall Recruitment Status
Completed
Study Start Date
March 1, 2021 (Actual)
Primary Completion Date
August 31, 2022 (Actual)
Study Completion Date
August 31, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Guangdong Provincial People's Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Catheter-related thrombosis could impair blood flow in the vein, block the central venous catheter, induce catheter-related infection or venous thromboembolism in the deep veins or pulmonary vessels, which furthermore progress into the post-thrombotic syndrome.
Researches using echogenic mass as the primary outcome could miss those premature thrombi which might not be seen on traditional ultrasonography but may be detected by Duplex and Doppler ultrasound with vessel compression. Moreover, studies indicated that some thrombus developed after the catheter removal. Removal of the catheter is not the endpoint of thrombus detection. This study is designed to determine the preventive effects of continuous heparin infusion on real-world central venous catheter-related thrombosis in infants after cardiac surgery.
Detailed Description
Catheter-related thrombosis could impair blood flow in the vein, block the central venous catheter, induce catheter-related infection or venous thromboembolism in the deep veins or pulmonary vessels, which furthermore progress into the post-thrombotic syndrome. Researches using echogenic mass as the primary outcome could miss those premature thrombi which might not be seen on traditional ultrasonography but may be detected by Duplex and Doppler ultrasound with vessel compression. Moreover, studies indicated that some thrombus developed after the catheter removal. Removal of the catheter is not the endpoint of thrombus detection. This study is designed to determine the preventive effects of continuous heparin infusion on real-world central venous catheter-related thrombosis in infants after cardiac surgery. One hundred and twenty-four infants were randomized to the intervention group or the control group. Unfractionated heparin or normal saline was infused continuously through each lumen of the central venous catheter at the speed of 0.5 ml/h/line until the catheter was removed. Catheter-related thrombosis was detected by point-of-care Duplex and Doppler ultrasound periodically until 30 days after the cardiac surgery or discharge, whichever comes first.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Surgery, Central Venous Catheter Thrombosis, Heparin
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Masking Description
Infant participants were blinded naturally, while ultrasonographers for central venous catheter (CVC)-related thrombosis were blinded, especially after interventions were stopped.
Allocation
Randomized
Enrollment
35 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Heparin group
Arm Type
Experimental
Arm Description
Continuous infusion of heparin was used to maintain the patency of CVC.
Arm Title
Control group
Arm Type
Placebo Comparator
Arm Description
Continuous infusion of heparin was used at the corresponding speed.
Intervention Type
Drug
Intervention Name(s)
Heparin sodium
Other Intervention Name(s)
unfractionated heparin
Intervention Description
For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h.
For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol.
Intervention Type
Drug
Intervention Name(s)
Normal saline
Intervention Description
For infants enrolled, normal saline was infused at the corresponding speed.
Primary Outcome Measure Information:
Title
124 infants of CVC-related thrombosis by point-of-care echography or ultrasound
Description
CVC-related thrombosis of any catheter as imaged by echocardiogram or ultrasound at 30 days after cardiac surgery. Thrombus was defined as an echogenic mass near the tip of the catheter or slow/no flow detected by Duplex and Doppler ultrasound at the nearby vessels and the on-site vessel couldn't be clasped as narrow as the collateral vessel by compression of the probe.
Time Frame
30 days after cardiac surgery or at discharge, whichever comes first
Secondary Outcome Measure Information:
Title
124 infants of heparin-related comorbidity
Description
Abnormal coagulation and hemostasis were defined as treatment initiation by the clinical teams at the discretion of heparin adverse events. Heparin-induced thrombocytopenia was confirmed with consistent low platelet level and positive enzyme-linked immunosorbent assay heparin-platelet factor 4 antibody assay. Catheter-related sepsis was defined as culture of the same organism from both the catheter tip and at least one percutaneous blood culture. Culture of the same organism from the catheter was also accepted as an alternative of culture of catheter tip.
Time Frame
30 days after cardiac surgery or at discharge, whichever comes first
Other Pre-specified Outcome Measures:
Title
Post-thrombotic syndrome
Description
The symptoms of post-thrombotic syndrome included aching, swelling, itchy and ulcer in the indwelling site and the collateral varicose veins.
Time Frame
6 months after cardiac surgery
10. Eligibility
Sex
All
Maximum Age & Unit of Time
3 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
less than 3 months of age at admission, post-cardiac surgery, with CVC indwelled
Exclusion Criteria:
parents' refusal, requiring postoperative anticoagulant administration (extracorporeal membrane oxygenation support, prosthetic devices), the contradiction to heparin (coagulopathy or hypercoagulable state, platelet level less than 50000/dL, clinically significant bleeding tendency, allergy to heparin)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yunxia Sun, MD
Organizational Affiliation
Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences
Official's Role
Principal Investigator
Facility Information:
Facility Name
Guangdong Provincial People's Hospital
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510080
Country
China
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
All data published and other related data were available after publication. No private information would be published.
IPD Sharing Time Frame
From the date of publication to 5 years after publication.
IPD Sharing Access Criteria
Requests to the corresponding author were necessary.
Learn more about this trial
Continuous Heparin Infusion to Prevent Catheter-related Thrombosis
We'll reach out to this number within 24 hrs